Chapter 2. Antimicrobial Resistance
Surveillance of Animal Clinical Isolates
Key Findings
Cattle
Salmonella (n = 177)
Salmonella Dublin was the most common serovar recovered from cattle (25%, 45/177); 7 isolates were resistant to 6 antimicrobial classes (all except macrolides), 44 isolates were resistant to = 4 classes, and 8 isolates were resistant to nalidixic acid (Table 48 and Table 53).
Chickens
Salmonella (n = 161)
Salmonella Heidelberg was the most common serovar from chickens (34%, 55/161) and 6 isolates were resistant to = 1 antimicrobial class (Table 49 and Table 54). One S. Enteritidis isolate was resistant to gentamicin and sulfisoxazole (Table 49 and Table 54).
Seventy percent (113/161) of all Salmonella isolates from chickens were non-resistant (Table 49 and Table 54).
Pigs
Salmonella (n = 255)
Resistance to nalidixic acid was observed in 1 S. Cubana isolate and 1 S. Typhimurium isolate (Table 50 and Table 55).
Turkeys
Salmonella (n = 58)
Two Salmonella Indiana isolates were resistant to all antimicrobial classes except the quinolones (Table 51). Resistance to nalidixic acid was observed in 1 S. Senftenberg isolate (Table 51 and Table 56).
Horses
Salmonella (n = 14)
Four S. Heidelberg isolates were resistant to 4 antimicrobial classes (Table 52).
Multiclass Resistance
| Serovar | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Dublin | 45 (25.4) | 1 | 37 | 7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33 | 44 | 44 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | 44 | |||||
| Typhimurium | 33 (18.6) | 16 | 1 | 2 | 14 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | 16 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 13 | 17 | ||||
| Typhimurium var. 5- | 32 (18.1) | 1 | 2 | 29 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 29 | 4 | 29 | |||||||
| 4,[5],12:i:- | 12 (6.8) | 6 | 1 | 1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 4 | ||||||
| Cerro | 9 (5.1) | 9 | |||||||||||||||||||
| Heidelberg | 7 (4.0) | 6 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 1 | ||||||||
| Thompson | 6 (3.4) | 6 | |||||||||||||||||||
| Enteritidis | 5 (2.8) | 1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 | 4 | 4 | 4 | ||||||||
| Less common serovars | 28 (15.8) | 21 | 1 | 4 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | 4 | 2 | 7 | ||||||
| Total | 177 (100) | 67 | 5 | 7 | 91 | 7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.47 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.47 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.47 | 103 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 68 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | 106 | |
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".
| Serovar | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Heidelberg | 55 (34.2) | 49 | 4 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 | 2 | ||||||||||
| Enteritidis | 26 (16.1) | 25 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | ||||||||||||||||
| Kentucky | 20 (12.4) | 3 | 3 | 14 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | 14 | ||||||||||
| 4,[5],12:i:- | 8 (5.0) | 6 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | |||||||||||||
| Senftenberg | 7 (4.3) | 5 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | |||||||||||||
| Agona | 6 (3.7) | 5 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 1 | 1 | 1 | |||||||||
| Anatum | 5 (3.1) | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | |||||||||||||||||
| Mbandaka | 5 (3.1) | 3 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 2 | 2 | |||||||||||||||
| Alachua | 4 (2.5) | 4 | |||||||||||||||||||
| Less common serovars | 25 (15.5) | 13 | 5 | 6 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 7 | |||||
| Total | 161 (100) | 113 | 16 | 30 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.24 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.24 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.24 | 7 | 1 | 2 | 26 | ||||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".
| Serovar | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Typhimurium | 74 (29) | 7 | 10 | 15 | 42 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | 50 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 33 | 63 | |||
| Typhimurium var. 5- | 36 (14.1) | 1 | 4 | 4 | 27 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 28 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | 25 | 32 | ||||||||
| I 4,[5],12:i:- | 25 (9.8) | 3 | 22 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 22 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 2 | 22 | ||||||
| Derby | 23 (9) | 4 | 3 | 14 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 15 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 2 | 18 | ||||
| Infantis | 19 (7.5) | 17 | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 1 | 2 | ||||||||||||
| Worthington | 11 (4.3) | 9 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 11 | ||||||||||
| Mbandaka | 7 (2.7) | 6 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 1 | |||||||||||||||
| Schwarzengrund | 7 (2.7) | 1 | 4 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 6 | 6 | |||||||||||||
| Less common serovars | 53 (20.8) | 22 | 5 | 16 | 10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 23 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | 8 | 1 | 30 | |||
| Total | 255 (100) | 61 | 31 | 57 | 106 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.131 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.127 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | 148 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 | 1 | 70 | 1 | 185 | ||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".
| Serovar | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Heidelberg | 14 (24.1) | 11 | 1 | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 2 | 2 | ||||||
| Agona | 12 (20.7) | 1 | 5 | 6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | 8 | 1 | 4 | 11 | ||||||
| Worthington | 5 (8.6) | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | 5 | 4 | ||||||||||||||
| Hadar | 3 (5.2) | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 3 | ||||||||||||||||
| Mbandaka | 3 (5.2) | 1 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 2 | 2 | ||||||||||||||
| Senftenberg | 3 (5.2) | 1 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 1 | 1 | ||||||||||||
| Albany | 2 (3.4) | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | |||||||||||||
| Indiana | 2 (3.4) | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Muenchen | 2 (3.4) | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 2 | 2 | |||||||||||||||
| Schwarzengrund | 2 (3.4) | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 2 | 2 | ||||||||||||||||
| Less common serovars | 10 (17.2) | 4 | 4 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | 1 | 1 | |||||||
| Total | 58 (100) | 18 | 7 | 24 | 7 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 | 25 | 3 | 2 | 6 | 1 | 29 | |
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".
| Serovar | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Heidelberg | 5 (35.7) | 1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 4 | |||||||
| Infantis | 2 (14.3) | 2 | |||||||||||||||||||
| Enteritidis | 1 (7.1) | 1 | |||||||||||||||||||
| Give | 1 (7.1) | 1 | |||||||||||||||||||
| Hartford | 1 (7.1) | 1 | |||||||||||||||||||
| Indiana | 1 (7.1) | 1 | |||||||||||||||||||
| Newport | 1 (7.1) | 1 | |||||||||||||||||||
| Senftenberg | 1 (7.1) | 1 | |||||||||||||||||||
| Typhimurium | 1 (7.1) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||
| Total | 14 (100) | 8 | 1 | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 5 | 1 | |||||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Minimum Inhibitory Concentrations
More details on how to interpret the minimum inhibitory concentrations (MICs) tables are provided in the CIPARS Annual Report 2012 – Chapter 1. Design and Methods.
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 177 | 4 | > 32 | 26.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.3 Table 53 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.9 | Table 53 - Footnote 2 | 26.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Ceftiofur | 177 | 1 | > 8 | 26.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 53 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 Table 53 - Footnote 2 | 25.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 177 | ≤ 0.25 | 32 | 26.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.4 | Table 53 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 53 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 | 0.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Ciprofloxacin | 177 | ≤ 0.015 | 0.03 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.5 | Table 53 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | 1.1 | Table 53 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| II | Ampicillin | 177 | > 32 | > 32 | 50.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.9 | Table 53 - Footnote 1 | Table 53 - Footnote 2 | 50.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Azithromycin | 177 | 4 | 8 | 0.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | 0.6 Table 53 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Cefoxitin | 177 | 2 | > 32 | 25.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 Table 53 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 Table 53 - Footnote 2 | 22.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Gentamicin | 177 | 0.50 | 1 | 4.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Table 53 - Footnote 1 | Table 53 - Footnote 2 | 4.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Kanamycin | 177 | ≤ 8 | > 64 | 26.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.0 | Table 53 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 53 - Footnote 2 | 25.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Nalidixic acid | 177 | 4 | 4 | 4.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 53 - Footnote 2 | 4.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Streptomycin | 177 | ≤ 32 | > 64 | 46.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.1 Table 53 - Footnote 2 | 41.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 177 | ≤ 0.12 | 0.25 | 4.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 | Table 53 - Footnote 2 | 4.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| III | Chloramphenicol | 177 | 8 | > 32 | 38.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.3 Table 53 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 53 - Footnote 2 | 38.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Sulfisoxazole | 177 | > 256 | > 256 | 58.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.6 | 58.2 Table 53 - Footnote 2 | |||
| Tetracycline | 177 | > 32 | > 32 | 59.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.1 Table 53 - Footnote 1 | Table 53 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 | 58.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 161 | ≤ 1 | > 32 | 14.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3 Table 54 - Footnote 1 | Table 54 - Footnote 2 | 14.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Ceftiofur | 161 | 1 | > 8 | 14.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 54 - Footnote 1 | Table 54 - Footnote 2 | 14.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Ceftriaxone | 161 | ≤ 0.25 | 16 | 14.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 54 - Footnote 1 | Table 54 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.0 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Ciprofloxacin | 161 | ≤ 0.015 | ≤ 0.015 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7 | Table 54 - Footnote 1 | Table 54 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||
| II | Ampicillin | 161 | ≤ 1 | > 32 | 19.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.0 | Table 54 - Footnote 1 | Table 54 - Footnote 2 | 19.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Azithromycin | 161 | 4 | 8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Table 54 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Cefoxitin | 161 | 2 | 32 | 14.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Table 54 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.3 Table 54 - Footnote 2 | 5.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Gentamicin | 161 | 0.50 | 1 | 0.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6 | Table 54 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 54 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Kanamycin | 161 | ≤ 8 | ≤ 8 | 1.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1 | Table 54 - Footnote 1 | Table 54 - Footnote 2 | 1.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Nalidixic acid | 161 | 4 | 4 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | 2.5Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. | Table 54 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Streptomycin | 161 | ≤ 32 | > 64 | 17.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.1 Table 54 - Footnote 2 | 14.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 161 | ≤ 0.12 | ≤ 0.12 | 0.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Table 54 - Footnote 2 | 0.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| III | Chloramphenicol | 161 | 8 | 8 | 1.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.4 Table 54 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 | Table 54 - Footnote 2 | 1.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Sulfisoxazole | 161 | 32 | 64 | 4.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.9 | 4.3 Table 54 - Footnote 2 | |||
| Tetracycline | 161 | ≤ 4 | > 32 | 16.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.9 Table 54 - Footnote 1 | Table 54 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.0 | 16.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 255 | 2 | 16 | 2.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.3 Table 55 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.4 Table 55 - Footnote 2 | 2.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Ceftiofur | 255 | 1 | 1 | 2.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3 Table 55 - Footnote 1 | Table 55 - Footnote 2 | 2.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 255 | <=0.25 | <=0.25 | 2.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4 | Table 55 - Footnote 1 | Table 55 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 | 0.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ciprofloxacin | 255 | <=0.015 | <=0.015 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Table 55 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4 | Table 55 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| II | Ampicillin | 255 | 4 | >32 | 49.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 | Table 55 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.4 Table 55 - Footnote 2 | 49.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Azithromycin | 255 | 4 | 8 | 0.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 | 0.4 Table 55 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Cefoxitin | 255 | 2 | 4 | 2.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 Table 55 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 Table 55 - Footnote 2 | 1.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Gentamicin | 255 | 0.50 | 1 | 3.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 | Table 55 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.6 Table 55 - Footnote 2 | 1.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Kanamycin | 255 | <=8 | >64 | 13.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4 Table 55 - Footnote 1 | Table 55 - Footnote 2 | 13.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Nalidixic acid | 255 | 4 | 4 | 0.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5 | Table 55 - Footnote 2 | 0.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Streptomycin | 255 | 64 | >64 | 51.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.1 Table 55 - Footnote 2 | 44.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 255 | <=0.12 | 2 | 9.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Table 55 - Footnote 2 | 9.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| III | Chloramphenicol | 255 | 8 | >32 | 27.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.6 Table 55 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.8 Table 55 - Footnote 2 | 26.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Sulfisoxazole | 255 | >256 | >256 | 58.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4 | 58.0 Table 55 - Footnote 2 | |
| Tetracycline | 255 | >32 | >32 | 72.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.5 Table 55 - Footnote 1 | Table 55 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.0 | 61.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 58 | <=1 | >32 | 29.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 Table 56 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 Table 56 - Footnote 2 | 25.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Ceftiofur | 58 | 1 | >8 | 32.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Table 56 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Table 56 - Footnote 2 | 31.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 58 | <=0.25 | 32 | 32.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.2 | Table 56 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Table 56 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 | 1.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Ciprofloxacin | 58 | <=0.015 | <=0.015 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 | Table 56 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Table 56 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| II | Ampicillin | 58 | <=1 | >32 | 41.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Table 56 - Footnote 1 | Table 56 - Footnote 2 | 41.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Azithromycin | 58 | 4 | 8 | 3.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.0 | 3.4 Table 56 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||
| Cefoxitin | 58 | 4 | >32 | 27.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 Table 56 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 Table 56 - Footnote 2 | 24.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Gentamicin | 58 | 1 | >16 | 17.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.8 | Table 56 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Table 56 - Footnote 2 | 15.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Kanamycin | 58 | <=8 | >64 | 17.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Table 56 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Table 56 - Footnote 2 | 15.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||||
| Nalidixic acid | 58 | 4 | 4 | 1.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Table 56 - Footnote 2 | 1.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Streptomycin | 58 | 64 | >64 | 50.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19.0 Table 56 - Footnote 2 | 31.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||||
| Trimethoprim-sulfamethoxazole | 58 | <=0.12 | 0.25 | 5.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Table 56 - Footnote 2 | 5.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| III | Chloramphenicol | 58 | 8 | >32 | 10.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.9 Table 56 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 | Table 56 - Footnote 2 | 10.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Sulfisoxazole | 58 | 64 | >256 | 43.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 | 43.1 Table 56 - Footnote 2 | |||
| Tetracycline | 58 | >32 | >32 | 50.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Table 56 - Footnote 1 | Table 56 - Footnote 2 | 50.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 14 | <=1 | 32 | 14.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.6Table 57 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.1Table 57 - Footnote 2 | 7.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Ceftiofur | 14 | 1 | >8 | 14.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.4 | Table 57 - Footnote 1 | Table 57 - Footnote 2 | 14.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 14 | <=0.25 | 16 | 14.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.7 | Table 57 - Footnote 1 | Table 57 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||
| Ciprofloxacin | 14 | <=0.015 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 | Table 57 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.6 | Table 57 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| II | Ampicillin | 14 | 2 | >32 | 42.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.3 | Table 57 - Footnote 1 | Table 57 - Footnote 2 | 42.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Azithromycin | 14 | 4 | 8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 | Table 57 - Footnote 2Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||
| Cefoxitin | 14 | 2 | 32 | 14.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 | Table 57 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.1Table 57 - Footnote 2 | 7.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Gentamicin | 14 | 0.50 | >16 | 28.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 | Table 57 - Footnote 1 | Table 57 - Footnote 2 | 28.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Kanamycin | 14 | <=8 | >64 | 28.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.4 | Table 57 - Footnote 1 | Table 57 - Footnote 2 | 28.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Nalidixic acid | 14 | 4 | 8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.6 | Table 57 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Streptomycin | 14 | <=32 | >64 | 28.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14.3Table 57 - Footnote 2 | 14.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 14 | <=0.12 | >4 | 28.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 | Table 57 - Footnote 2 | 28.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| III | Chloramphenicol | 14 | 8 | >32 | 35.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.1Table 57 - Footnote 1 | Table 57 - Footnote 2 | 35.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Sulfisoxazole | 14 | 64 | >256 | 35.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 | 35.7Table 57 - Footnote 2 | ||||
| Tetracycline | 14 | <=4 | <=4 | 7.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.9Table 57 - Footnote 1 | Table 57 - Footnote 2 | 7.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| IV | |||||||||||||||||||||
Page details
- Date modified: